[ET Net News Agency, 1 June 2021] Sino Biopharmaceutical Limited (01177) said
"Tolvaptan Tablets" (brand name: Xinsuan), a new diuretic drug developed by the group, has
obtained drug registration certificate granted by the National Medical Products
Administration of the People's Republic of China and is deemed to have passed the
Consistency of Quality and Efficacy Evaluation for Generic Drugs.
Tolvaptan is a selective vasopressin V2 receptor antagonist, which can inhibit the
reabsorption of water in renal collecting ducts, thereby increasing the urinary excretion
of free water. (RC)